Lupus Science & Medicine

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Lupus Science & Medicine

Qualitative interview study in patients with SLE to assess patient perception of fatigue and skin-related symptoms

Objective SLE is a chronic autoimmune disorder with a range of symptoms. While these are broadly reported in the literature, ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Lupus Science & Medicine

Prognostic value of baseline clinical features in SLE: a cluster analysis

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
lupus.bmj

Prediction of prognosis and renal outcome in lupus nephritis

Lupus nephritis (LN) is a severe manifestation of SLE, characterised by subendothelial and/or subepithelial immune complex depositions in the afflicted kidney, resulting in extensive injury and ...
lupus.bmj

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort

Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts ...
lupus.bmj

Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms

Objective Manifestations of SLE can be categorised as type 1 (classic signs and symptoms of SLE) or type 2 (fatigue, widespread pain and brain fog with an unclear relationship to inflammation). While ...
lupus.bmj

Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis

Objective To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term ...
lupus.bmj

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus

Objective Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel ...
lupus.bmj

Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus

Objective This study aimed to characterise the clinical features and treatment regimens of patients with lupus who have lymphadenopathy (LAP), as well as to investigate the presence and potential ...